Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLY: Anticoagulation + Antiplatelet in Stroke
NCT06058130Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2023
- Primary completion
- Oct 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, single-blind trial of aspirin, clopidogrel, ticagrelor and cilostazol in ischemic stroke (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: 90-day Composite events. Started Sep 2023; status: recruiting.
02
Drugs
aspirinclopidogrelticagrelorcilostazol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06058130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06058130.